Katherine Hill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katherine Hill has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Kimberly L. Sue
Yale Program in Addiction Medicine, Yale School of Medicine, New Haven, CT, USA
9 shared publicationsKirsten E. Smith
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
6 shared publicationsRobert Heimer
Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
6 shared publications- Kirsten Elin Smith
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
4 shared publications - Oliver Grundmann
Department of Medicinal Chemistry, College of Pharmacy, University of Florida
4 shared publications Cameron Breen
Liberation Programs, Bridgeport, CT, USA
3 shared publications
Latest Publications
- 6 October 2026
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- p. 1-10
Semi-synthetic kratom derivatives in the Czech online market prior to regulatory reform: a baseline surveillance study
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia that is recognized for its psychoactive properties and distinctive pharmacological profile (1). More than 50 alkaloids have b...
- 6 October 2026
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- p. 1-10
Semi-synthetic kratom derivatives in the Czech online market prior to regulatory reform: a baseline surveillance study
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia that is recognized for its psychoactive properties and distinctive pharmacological profile (1). More than 50 alkaloids have b...
- Open Access
- 23 September 2026
- Published by SAGE Publications in Substance use & addiction journal
The 5 Senses Framework—People Who Use Drugs Were and Are the First Drug Checkers
Background: The unregulated drug supply in the United States has become largely unpredictable, with novel substances emerging and impacting the health and wellbeing of people who use drugs (PWUD). In response to this, harm reduction programs have increased funding for community-based drug checking to empower PWUD to learn about their drug supply. However, important implementation questions must be answered to ensure benefits are maximized. Thus, we aimed to create a conceptual framework to help community partners understand the imperative for including PWUD’s input on drug checking implementation. Findings: The 5 Senses Framework describes how PWUD use their sensory data (ie, sight, taste, smell, touch, hearing) and embodied sensations to evaluate their drug supply, allowing them to create informal mental archives of drug use experiences and adjust decision-making as needed to keep themselves safe in the future. PWUD’s intimate understanding of the drug supply makes them the first drug checkers, and thus important members of drug checking programs. The creation of a structured intake process that reflects the sensory experiences of PWUD may help engage individuals while recognizing their autonomy and foundational knowledge in the drug checking space. Understanding that PWUD are checking their drugs through sensory input and embodied sensations may help programs assess why some people may be hesitant to engage with drug checking more formally. Recognizing that PWUD may have expectations that differ from what existing programs provide is imperative for implementation, access and success. Additionally, PWUD often are part of communities that already share sensory knowledge about drugs. Building upon such networks may expand drug checking programs’ community benefit. Conclusion: Community-based drug checking programs would be wise to incorporate decision-making from PWUD, as they were, and are, the first drug checkers. Including sensory data during drug checking intake would position PWUD as integral team members.
- 23 September 2026
- Published by SAGE Publications in Substance use & addiction journal
Open AccessThe 5 Senses Framework—People Who Use Drugs Were and Are the First Drug Checkers
Background: The unregulated drug supply in the United States has become largely unpredictable, with novel substances emerging and impacting the health and wellbeing of people who use drugs (PWUD). In response to this, harm reduction programs have increased funding for community-based drug checking to empower PWUD to learn about their drug supply. However, important implementation questions must be answered to ensure benefits are maximized. Thus, we aimed to create a conceptual framework to help community partners understand the imperative for including PWUD’s input on drug checking implementation. Findings: The 5 Senses Framework describes how PWUD use their sensory data (ie, sight, taste, smell, touch, hearing) and embodied sensations to evaluate their drug supply, allowing them to create informal mental archives of drug use experiences and adjust decision-making as needed to keep themselves safe in the future. PWUD’s intimate understanding of the drug supply makes them the first drug checkers, and thus important members of drug checking programs. The creation of a structured intake process that reflects the sensory experiences of PWUD may help engage individuals while recognizing their autonomy and foundational knowledge in the drug checking space. Understanding that PWUD are checking their drugs through sensory input and embodied sensations may help programs assess why some people may be hesitant to engage with drug checking more formally. Recognizing that PWUD may have expectations that differ from what existing programs provide is imperative for implementation, access and success. Additionally, PWUD often are part of communities that already share sensory knowledge about drugs. Building upon such networks may expand drug checking programs’ community benefit. Conclusion: Community-based drug checking programs would be wise to incorporate decision-making from PWUD, as they were, and are, the first drug checkers. Including sensory data during drug checking intake would position PWUD as integral team members.
- 15 September 2026
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
“Rhino Tranq” in Connecticut—Prevalence of Medetomidine in the Fentanyl Supply Varies by Data Source
Background: Medetomidine, a veterinary sedative, has emerged as an adulterant in the unregulated fentanyl supply. Exposure may cause profound sedation and a severe withdrawal syndrome. We aimed to better estimate medetomidine prevalence by integrating multiple statewide datasets from Connecticut. Methods: We analyzed 4 datasets from 2025: (a) accidental overdose fatalities, (b) drug seizure testing, (c) driving under the influence (DUI) toxicology, and (d) community-based drug checking using medetomidine test strips (MTS) and field-based Fourier-transform infrared spectroscopy (FTIR). Analyses were restricted to fentanyl-involved cases/samples, and medetomidine prevalence was calculated for each source. Results: Among 579 fentanyl-involved overdose fatalities, medetomidine was detected in 1.4%—though confirmatory testing was limited. Of 259 fentanyl seizure units tested, 41.7% contained medetomidine. Among 177 fentanyl-involved DUI cases, 24.9% were positive for medetomidine on toxicology. There were 169 samples of fentanyl/heroin/dope submitted to community-based drug checking programs that subsequently tested positive for fentanyl and assessed for medetomidine: MTS yielded positive results in 46.2% of samples on average, while FTIR detected medetomidine in 28.4% of samples. Conclusions: This study not only demonstrated that medetomidine is prevalent in the street-based fentanyl supply, but that the prevalence varied by data source. The findings highlight that surveillance mechanisms that rely exclusively on a single data source (typically overdose toxicology data) may misrepresent the true presence of medetomidine in the street supply.
- 15 September 2026
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
“Rhino Tranq” in Connecticut—Prevalence of Medetomidine in the Fentanyl Supply Varies by Data Source
Background: Medetomidine, a veterinary sedative, has emerged as an adulterant in the unregulated fentanyl supply. Exposure may cause profound sedation and a severe withdrawal syndrome. We aimed to better estimate medetomidine prevalence by integrating multiple statewide datasets from Connecticut. Methods: We analyzed 4 datasets from 2025: (a) accidental overdose fatalities, (b) drug seizure testing, (c) driving under the influence (DUI) toxicology, and (d) community-based drug checking using medetomidine test strips (MTS) and field-based Fourier-transform infrared spectroscopy (FTIR). Analyses were restricted to fentanyl-involved cases/samples, and medetomidine prevalence was calculated for each source. Results: Among 579 fentanyl-involved overdose fatalities, medetomidine was detected in 1.4%—though confirmatory testing was limited. Of 259 fentanyl seizure units tested, 41.7% contained medetomidine. Among 177 fentanyl-involved DUI cases, 24.9% were positive for medetomidine on toxicology. There were 169 samples of fentanyl/heroin/dope submitted to community-based drug checking programs that subsequently tested positive for fentanyl and assessed for medetomidine: MTS yielded positive results in 46.2% of samples on average, while FTIR detected medetomidine in 28.4% of samples. Conclusions: This study not only demonstrated that medetomidine is prevalent in the street-based fentanyl supply, but that the prevalence varied by data source. The findings highlight that surveillance mechanisms that rely exclusively on a single data source (typically overdose toxicology data) may misrepresent the true presence of medetomidine in the street supply.
- 13 July 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (4) , 995-1005
Upstream Overdose Prevention: Why the US Should Pilot a Safer, Regulated Drug Supply
The United States overdose crisis is driven in large part by an increasingly unpredictable and contaminated drug supply, including fentanyl and its analogs and emerging adulterants such as xylazine and nitazenes. Drug checking interventions such as fentanyl test strips and Fourier Transform Infrared Spectroscopy are essential for harm reduction, yet they also highlight a central policy failure: they place the burden of safety on people who use drugs (PWUD) and frontline programs after drugs have already entered an unregulated market. We argue for a more pragmatic upstream public health response, authorizing pilots of a safer, regulated drug supply (“safer supply”), broadly defined as legal and regulated access to psychoactive substances or close pharmaceutical alternatives intended to reduce reliance on the unregulated drug market. International experience, particularly models in Switzerland, Canada, and the United Kingdom, demonstrates feasibility and suggests potential benefits, including improved health and social stability, reduced reliance on unregulated supply, and reduced acute care utilization in some settings. For the United States context, we propose a portfolio approach: near-term, healthcare-based pilots leveraging existing controlled-substance infrastructure (eg, opioid treatment programs, clinics, pharmacies, and tech-enabled dispensing) while preserving space for community-governed models with legal protections and longer-horizon, state-regulated pathways. We address predictable concerns (secondary sharing, youth initiation, community impact, mixed population-level findings) and outline guardrails and evaluation strategies that are PWUD-led, nonpunitive, and methodologically rigorous. We conclude with concrete policy actions to authorize pilots, establish legal protections, fund independent evaluation, and scale models that demonstrably reduce harm while integrating with harm reduction and treatment services.
- 13 July 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (4) , 995-1005
Upstream Overdose Prevention: Why the US Should Pilot a Safer, Regulated Drug Supply
The United States overdose crisis is driven in large part by an increasingly unpredictable and contaminated drug supply, including fentanyl and its analogs and emerging adulterants such as xylazine and nitazenes. Drug checking interventions such as fentanyl test strips and Fourier Transform Infrared Spectroscopy are essential for harm reduction, yet they also highlight a central policy failure: they place the burden of safety on people who use drugs (PWUD) and frontline programs after drugs have already entered an unregulated market. We argue for a more pragmatic upstream public health response, authorizing pilots of a safer, regulated drug supply (“safer supply”), broadly defined as legal and regulated access to psychoactive substances or close pharmaceutical alternatives intended to reduce reliance on the unregulated drug market. International experience, particularly models in Switzerland, Canada, and the United Kingdom, demonstrates feasibility and suggests potential benefits, including improved health and social stability, reduced reliance on unregulated supply, and reduced acute care utilization in some settings. For the United States context, we propose a portfolio approach: near-term, healthcare-based pilots leveraging existing controlled-substance infrastructure (eg, opioid treatment programs, clinics, pharmacies, and tech-enabled dispensing) while preserving space for community-governed models with legal protections and longer-horizon, state-regulated pathways. We address predictable concerns (secondary sharing, youth initiation, community impact, mixed population-level findings) and outline guardrails and evaluation strategies that are PWUD-led, nonpunitive, and methodologically rigorous. We conclude with concrete policy actions to authorize pilots, establish legal protections, fund independent evaluation, and scale models that demonstrably reduce harm while integrating with harm reduction and treatment services.
- Open Access
- 5 May 2026
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 21
Kava (Piper methysticum) consumption patterns and conceptualizations: results from an online survey
Background: ‘Kava,’ or ‘kava kava,’ ( Piper methysticum ) is a psychoactive plant indigenous to the Pacific Islands. Historical consumption is reported to provide anxiolytic and sedating effects. In regions where kava is native, it has been used in religious and cultural practices, as well as for medicinal purposes. The mechanisms by which kavalactones – the best studied psychoactive constituent of kava – may mediate pharmacological effects include enhancing the GABA A receptor, blocking of sodium and calcium channels, blocking reuptake of norepinephrine dopamine, and inhibiting MAO-B. In the United States, products containing kava have proliferated in recent years alongside the rise of ethnobotanical tea bars serving kava preparations. Methods: Between December–July 2024, an anonymous online survey on legal psychoactive products was conducted using convenience sampling. Eligible individuals had to be ≥ 18 years old and endorse lifetime use of kratom, kava, tianeptine, and/or akuamma seed. Results: Of the 368 participants, almost half ( n = 180, 48.9%) had used kava during their lifetime. Those who reported lifetime use of kava were younger on average ( p = 0.001), more racially diverse ( p = 0.041), and had a higher proportion of being employed or in school ( p = 0.012) than those where did not use kava in their lifetime. Kava was purchased online (40.6%) or in ethnobotanical tea bars (31.7%). Many reported infrequent consumption (average = 4.4 months/year and 9.1 days/30 days). Lifetime use of alcohol, kratom, and cannabis was common. Approximately one-third of participants had consumed kava more than 100 times, with commonly reported perceived effects from kava experienced in the minutes and hours after consumption included reduced general anxiety (33.7%), improved mood (32.9%), reduced social anxiety (25.5%), and sedation (23.4%). Most respondents had favorable conceptualizations of kava, with only 11.7% characterizing that kava alone as habit-forming. Many (51.7%) conceptualized kava as an alcohol replacement with 18.3% and 16.7% using kava as a short- and/or long-term substitute for alcohol, respectively. Conclusions: Kava use practices are diverse, though perceived kava effects appear mostly mild. The proliferation and diversification of kava products pre-mixed with other psychoactive botanicals requires study as the benefit-risk profile may change. Clinicians should be aware of kava use for harm-reduction and other purposes.
- 5 May 2026
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 21
Open AccessKava (Piper methysticum) consumption patterns and conceptualizations: results from an online survey
Background: ‘Kava,’ or ‘kava kava,’ ( Piper methysticum ) is a psychoactive plant indigenous to the Pacific Islands. Historical consumption is reported to provide anxiolytic and sedating effects. In regions where kava is native, it has been used in religious and cultural practices, as well as for medicinal purposes. The mechanisms by which kavalactones – the best studied psychoactive constituent of kava – may mediate pharmacological effects include enhancing the GABA A receptor, blocking of sodium and calcium channels, blocking reuptake of norepinephrine dopamine, and inhibiting MAO-B. In the United States, products containing kava have proliferated in recent years alongside the rise of ethnobotanical tea bars serving kava preparations. Methods: Between December–July 2024, an anonymous online survey on legal psychoactive products was conducted using convenience sampling. Eligible individuals had to be ≥ 18 years old and endorse lifetime use of kratom, kava, tianeptine, and/or akuamma seed. Results: Of the 368 participants, almost half ( n = 180, 48.9%) had used kava during their lifetime. Those who reported lifetime use of kava were younger on average ( p = 0.001), more racially diverse ( p = 0.041), and had a higher proportion of being employed or in school ( p = 0.012) than those where did not use kava in their lifetime. Kava was purchased online (40.6%) or in ethnobotanical tea bars (31.7%). Many reported infrequent consumption (average = 4.4 months/year and 9.1 days/30 days). Lifetime use of alcohol, kratom, and cannabis was common. Approximately one-third of participants had consumed kava more than 100 times, with commonly reported perceived effects from kava experienced in the minutes and hours after consumption included reduced general anxiety (33.7%), improved mood (32.9%), reduced social anxiety (25.5%), and sedation (23.4%). Most respondents had favorable conceptualizations of kava, with only 11.7% characterizing that kava alone as habit-forming. Many (51.7%) conceptualized kava as an alcohol replacement with 18.3% and 16.7% using kava as a short- and/or long-term substitute for alcohol, respectively. Conclusions: Kava use practices are diverse, though perceived kava effects appear mostly mild. The proliferation and diversification of kava products pre-mixed with other psychoactive botanicals requires study as the benefit-risk profile may change. Clinicians should be aware of kava use for harm-reduction and other purposes.
- Open Access
- 2 May 2026
- Published by Springer Nature in Harm Reduction Journal
- Vol. 23 (1)
Crack/cocaine use to manage xylazine exposure in fentanyl in Connecticut: findings from a convergent mixed methods study
Background: In the context of the fourth wave of the opioid overdose crisis, defined by fentanyl and stimulant co-use, we aimed to explore if there might be a relationship between exposure to xylazine in the fentanyl supply and patterns of crack/cocaine use. Methods: This mixed methods study used data from four Connecticut-based sources: (1) the Office of the Chief Medical Examiner for fatal overdoses, 2019–2023, (2) community-based drug checking data, 2023–2024, (3) a structured survey of people who use drugs, 2024, and (4) one-on-one in-depth interviews, 2024. Results: Xylazine was detected in 19.2% of overdose fatalities involving fentanyl or a fentanyl analog ( n = 5,849). Those with xylazine detected had a higher proportion of cocaine simultaneously detected, though this was not statistically significant (54.0% vs. 51.1%, p = 0.085). Cocaine detection rose over time in the fatality data, regardless of xylazine detection. There were 1,048 drug samples submitted to harm reduction organizations for drug checking. Using Fourier Transform Infrared Spectroscopy, 573 of the samples submitted tested positive for fentanyl or a fentanyl analog; 45.2% of these also tested positive for xylazine. Of 1048 samples, 276 tested positive for cocaine. Among the survey sample ( n = 88), 62.5% of participants self-reported xylazine exposure. Those who reported lifetime xylazine exposure also reported higher past-year crack/cocaine use, though this was not statistically significant (89.1% vs. 81.8%, p = 0.336). Among our interview sample ( n = 31), three themes emerged: (1) participants felt there was an inevitability of polysubstance use due to an increasingly volatile drug supply, (2) participants increased their crack/cocaine use in response to perceived exposure to xylazine in their fentanyl supply, and (3) participants’ drug patterning changed due to xylazine’s presence (e.g., timing, drug sequencing, etc.). Two meta-inferences were identified: (1) overdose fatality data likely underestimate the “true” prevalence of xylazine in the street supply, and (2) people who use drugs are using crack/cocaine in response to xylazine in their local fentanyl supply. Conclusions: Xylazine exposure has likely contributed to an adaptive and increasing use of crack/cocaine among people who use drugs in Connecticut. It is imperative that practitioners and policymakers are prepared to manage this triad of opioid-stimulant-sedative polysubstance use.
- 2 May 2026
- Published by Springer Nature in Harm Reduction Journal
- Vol. 23 (1)
Open AccessCrack/cocaine use to manage xylazine exposure in fentanyl in Connecticut: findings from a convergent mixed methods study
Background: In the context of the fourth wave of the opioid overdose crisis, defined by fentanyl and stimulant co-use, we aimed to explore if there might be a relationship between exposure to xylazine in the fentanyl supply and patterns of crack/cocaine use. Methods: This mixed methods study used data from four Connecticut-based sources: (1) the Office of the Chief Medical Examiner for fatal overdoses, 2019–2023, (2) community-based drug checking data, 2023–2024, (3) a structured survey of people who use drugs, 2024, and (4) one-on-one in-depth interviews, 2024. Results: Xylazine was detected in 19.2% of overdose fatalities involving fentanyl or a fentanyl analog ( n = 5,849). Those with xylazine detected had a higher proportion of cocaine simultaneously detected, though this was not statistically significant (54.0% vs. 51.1%, p = 0.085). Cocaine detection rose over time in the fatality data, regardless of xylazine detection. There were 1,048 drug samples submitted to harm reduction organizations for drug checking. Using Fourier Transform Infrared Spectroscopy, 573 of the samples submitted tested positive for fentanyl or a fentanyl analog; 45.2% of these also tested positive for xylazine. Of 1048 samples, 276 tested positive for cocaine. Among the survey sample ( n = 88), 62.5% of participants self-reported xylazine exposure. Those who reported lifetime xylazine exposure also reported higher past-year crack/cocaine use, though this was not statistically significant (89.1% vs. 81.8%, p = 0.336). Among our interview sample ( n = 31), three themes emerged: (1) participants felt there was an inevitability of polysubstance use due to an increasingly volatile drug supply, (2) participants increased their crack/cocaine use in response to perceived exposure to xylazine in their fentanyl supply, and (3) participants’ drug patterning changed due to xylazine’s presence (e.g., timing, drug sequencing, etc.). Two meta-inferences were identified: (1) overdose fatality data likely underestimate the “true” prevalence of xylazine in the street supply, and (2) people who use drugs are using crack/cocaine in response to xylazine in their local fentanyl supply. Conclusions: Xylazine exposure has likely contributed to an adaptive and increasing use of crack/cocaine among people who use drugs in Connecticut. It is imperative that practitioners and policymakers are prepared to manage this triad of opioid-stimulant-sedative polysubstance use.
- Open Access
- 3 April 2026
- Published by Springer Nature in Harm Reduction Journal
- Vol. 23 (1)
Zeroing in on xylazine - a mixed methods study to explore correlates of reported xylazine use and educational gaps among people who use drugs
Background: Xylazine prevalence has surged in the unregulated fentanyl supply across the United States. In efforts to inform education initiatives for people who use drugs, this study aimed to identify factors associated with reported xylazine use and knowledge gaps. Methods: This Connecticut-based mixed methods study employed both surveys and interviews. Survey participants, recruited from collaborating harm reduction organizations, were adults who used unregulated substances in the last six months. They were asked about their drug use, knowledge of xylazine, service use experience, and demographic information. Purposive sampling of survey participants was then used to select individuals for in-depth interviews. Topic guides were designed to gain a deeper understanding of participants’ xylazine awareness and future learning preferences. Quantitative data were dichotomized based on reported xylazine use and analyzed using descriptive statistics, Chi-square, Fisher’s exact, or t-tests. Simple and multiple logistic regression were used to find correlates of reported use of xylazine. Interviews were analyzed using thematic analysis. Results: Between August and November 2024, we surveyed 114 respondents. Nearly half reported lifetime xylazine use (49.1%) and almost three-quarters heard of xylazine prior to engaging in the study (71.9%). Multiple logistic regression revealed that unemployment (OR 6.5, 95% CI 2.4–17.8), past-year fentanyl use (OR 41.1, 95% CI 4.8–354.4), and harm reduction service engagement (OR 5.2, 95% CI 1.6–16.8) as predictors of reported xylazine use, after adjustments. We conducted n=31 interviews; thematic analysis identified four major themes: (1) information about xylazine was obtained from many sources, (2) knowledge about xylazine was gained from using xylazine, (3) some misconceptions about xylazine have developed, and (4) multiple mechanisms for xylazine education are desired. Conclusions: This study underscores the need for accessible xylazine education to address knowledge and confidence gaps among people who use drugs. Xylazine education should be tailored to one’s likely xylazine exposure. Education must be harm-reduction oriented, stigma-free, and incorporate the voices of people who use drugs.
- 3 April 2026
- Published by Springer Nature in Harm Reduction Journal
- Vol. 23 (1)
Open AccessZeroing in on xylazine - a mixed methods study to explore correlates of reported xylazine use and educational gaps among people who use drugs
Background: Xylazine prevalence has surged in the unregulated fentanyl supply across the United States. In efforts to inform education initiatives for people who use drugs, this study aimed to identify factors associated with reported xylazine use and knowledge gaps. Methods: This Connecticut-based mixed methods study employed both surveys and interviews. Survey participants, recruited from collaborating harm reduction organizations, were adults who used unregulated substances in the last six months. They were asked about their drug use, knowledge of xylazine, service use experience, and demographic information. Purposive sampling of survey participants was then used to select individuals for in-depth interviews. Topic guides were designed to gain a deeper understanding of participants’ xylazine awareness and future learning preferences. Quantitative data were dichotomized based on reported xylazine use and analyzed using descriptive statistics, Chi-square, Fisher’s exact, or t-tests. Simple and multiple logistic regression were used to find correlates of reported use of xylazine. Interviews were analyzed using thematic analysis. Results: Between August and November 2024, we surveyed 114 respondents. Nearly half reported lifetime xylazine use (49.1%) and almost three-quarters heard of xylazine prior to engaging in the study (71.9%). Multiple logistic regression revealed that unemployment (OR 6.5, 95% CI 2.4–17.8), past-year fentanyl use (OR 41.1, 95% CI 4.8–354.4), and harm reduction service engagement (OR 5.2, 95% CI 1.6–16.8) as predictors of reported xylazine use, after adjustments. We conducted n=31 interviews; thematic analysis identified four major themes: (1) information about xylazine was obtained from many sources, (2) knowledge about xylazine was gained from using xylazine, (3) some misconceptions about xylazine have developed, and (4) multiple mechanisms for xylazine education are desired. Conclusions: This study underscores the need for accessible xylazine education to address knowledge and confidence gaps among people who use drugs. Xylazine education should be tailored to one’s likely xylazine exposure. Education must be harm-reduction oriented, stigma-free, and incorporate the voices of people who use drugs.
- 17 March 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 628-638
In Support of Harm Reduction Supply Distribution Via Vending Machines: Position Statement of AMERSA, Inc.
Background: Harm reduction services fulfill a critical need in reducing the negative consequences associated with the overdose crisis. However, many current evidence-based harm reduction services—such as syringe service programs—have access barriers including limited hours or the need for face-to-face interactions to help serve people who use drugs (PWUD). Issue: To complement such traditional services, overcome barriers, and bridge gaps, harm reduction vending machines (HRVMs) are increasingly being used to offer PWUD low-barrier, 24-hour access to harm reduction supplies, such as naloxone, drug-checking strips, condoms, and more. Evidence from around the world, and more recently in the United States, demonstrates that HRVMs not only provide anonymous no- or low-cost supplies to PWUD, but also do so in ways that overcome key barriers such as stigma, cost, and transportation, while also increasing accessibility and acceptability among PWUD. Perhaps most notably, HRVMs can do all of this while remaining cost-efficient, highly accessible, and adaptable to community needs. Recommendations: Accordingly, the Association for Multidisciplinary Education and Research in Substance Use and Addiction supports funding and research for the broader application of HRVMs, alongside the creation of national implementation guidance and federal and state policy alignment, to ensure that communities across the United States can access these crucial harm reduction services.
- 17 March 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 628-638
In Support of Harm Reduction Supply Distribution Via Vending Machines: Position Statement of AMERSA, Inc.
Background: Harm reduction services fulfill a critical need in reducing the negative consequences associated with the overdose crisis. However, many current evidence-based harm reduction services—such as syringe service programs—have access barriers including limited hours or the need for face-to-face interactions to help serve people who use drugs (PWUD). Issue: To complement such traditional services, overcome barriers, and bridge gaps, harm reduction vending machines (HRVMs) are increasingly being used to offer PWUD low-barrier, 24-hour access to harm reduction supplies, such as naloxone, drug-checking strips, condoms, and more. Evidence from around the world, and more recently in the United States, demonstrates that HRVMs not only provide anonymous no- or low-cost supplies to PWUD, but also do so in ways that overcome key barriers such as stigma, cost, and transportation, while also increasing accessibility and acceptability among PWUD. Perhaps most notably, HRVMs can do all of this while remaining cost-efficient, highly accessible, and adaptable to community needs. Recommendations: Accordingly, the Association for Multidisciplinary Education and Research in Substance Use and Addiction supports funding and research for the broader application of HRVMs, alongside the creation of national implementation guidance and federal and state policy alignment, to ensure that communities across the United States can access these crucial harm reduction services.
- 21 January 2026
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- p. 1-8
Akuamma Seed ( Picralima nitida ) Use in the U.S.: Findings from a Web-Based Survey
Indigenous to West Africa, akuamma seed (Picralima nitida) is used in traditional medicine and demonstrates opioidergic activity. Little is known about its role in management of pain or other ailments among people in the United States. This study presents findings from a web-based survey conducted between December 2023 and July 2024. Summary statistics characterized individuals reporting lifetime akuamma seed use, including demographics, substance use history, pain severity, and motivations. Between-group comparisons were conducted for those with and without lifetime akuamma seed use. Among 369 participants, 28 (7.6%) reported lifetime akuamma seed use. Those with lifetime akuamma seed use were older (44.7 years, p = .04), females (64.3%, p = .004), or currently disabled (32.1%, p < .001). They reported less alcohol (p = .033), more kava (78.6%, p = .001) and Delta-8 THC (71.4%, p < .001) use; all had tried kratom. Those who had tried akuamma seed indicated greater pain severity and reported use for pain management and opioid substitution; 60.7% reported pain relief from akuamma seed. No participants met DSM-5 criteria for akuamma seed-related substance use disorder modified. Akuamma seed may be used in the United States alongside other unscheduled psychoactive substances, particularly, psychoactive botanical-derived products. Additional research is needed to evaluate safety, efficacy, and health outcomes associated with akuamma seed.
- 21 January 2026
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- p. 1-8
Akuamma Seed ( Picralima nitida ) Use in the U.S.: Findings from a Web-Based Survey
Indigenous to West Africa, akuamma seed (Picralima nitida) is used in traditional medicine and demonstrates opioidergic activity. Little is known about its role in management of pain or other ailments among people in the United States. This study presents findings from a web-based survey conducted between December 2023 and July 2024. Summary statistics characterized individuals reporting lifetime akuamma seed use, including demographics, substance use history, pain severity, and motivations. Between-group comparisons were conducted for those with and without lifetime akuamma seed use. Among 369 participants, 28 (7.6%) reported lifetime akuamma seed use. Those with lifetime akuamma seed use were older (44.7 years, p = .04), females (64.3%, p = .004), or currently disabled (32.1%, p < .001). They reported less alcohol (p = .033), more kava (78.6%, p = .001) and Delta-8 THC (71.4%, p < .001) use; all had tried kratom. Those who had tried akuamma seed indicated greater pain severity and reported use for pain management and opioid substitution; 60.7% reported pain relief from akuamma seed. No participants met DSM-5 criteria for akuamma seed-related substance use disorder modified. Akuamma seed may be used in the United States alongside other unscheduled psychoactive substances, particularly, psychoactive botanical-derived products. Additional research is needed to evaluate safety, efficacy, and health outcomes associated with akuamma seed.
- Open Access
- 18 November 2025
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 32 (1) , 34-43
An Approach to Building a Strong Public Health Workforce: The Connecticut Public Health Fellowship Program
Context: The public health (PH) workforce shortage poses a significant threat to the US population. Despite an increase in PH programs attracting students, there is a need to enhance diversity within local and state PH departments. While internships are recognized as valuable entry points into the PH field, research on the effectiveness of such pathway programs for recruiting diverse candidates is limited. Program: Sponsored by the Connecticut (CT) Department of Public Health and supported by the CDC Crisis Response Cooperative Agreement: COVID-19 Public Health Workforce Supplemental Funding, the CT Public Health Fellowship Program (PHFP) aims to generate interest in PH careers by placing students in high-quality fellowship positions in CT. Third- or fourth-year undergraduates and graduate students enrolled in PH programs receive administrative support, one-on-one coaching, orientation, and a $3500 stipend to facilitate their internships. Implementation: From January 2023 to May 2024, 97 out of 205 applicants were admitted to the PHFP. Acceptance was on a rolling basis, accommodating academic schedules, personal limitations such as work/family obligation or transportation access, and host agency capacities. Evaluation: We analyzed program data from PHFP applications. Chi-square tests and t -tests were conducted to assess differences between PHFP fellows and non-fellows. The results were not statistically significant. Additionally, fellows were compared to a representative sample of PH students from the US, New England, and CT. Discussion: The PHFP has a strong potential to help replenish and diversify the PH workforce and enhance health equity. Future research should examine the long-term impacts of such PH experiential learning initiatives on a large scale.
- 18 November 2025
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 32 (1) , 34-43
Open AccessAn Approach to Building a Strong Public Health Workforce: The Connecticut Public Health Fellowship Program
Context: The public health (PH) workforce shortage poses a significant threat to the US population. Despite an increase in PH programs attracting students, there is a need to enhance diversity within local and state PH departments. While internships are recognized as valuable entry points into the PH field, research on the effectiveness of such pathway programs for recruiting diverse candidates is limited. Program: Sponsored by the Connecticut (CT) Department of Public Health and supported by the CDC Crisis Response Cooperative Agreement: COVID-19 Public Health Workforce Supplemental Funding, the CT Public Health Fellowship Program (PHFP) aims to generate interest in PH careers by placing students in high-quality fellowship positions in CT. Third- or fourth-year undergraduates and graduate students enrolled in PH programs receive administrative support, one-on-one coaching, orientation, and a $3500 stipend to facilitate their internships. Implementation: From January 2023 to May 2024, 97 out of 205 applicants were admitted to the PHFP. Acceptance was on a rolling basis, accommodating academic schedules, personal limitations such as work/family obligation or transportation access, and host agency capacities. Evaluation: We analyzed program data from PHFP applications. Chi-square tests and t -tests were conducted to assess differences between PHFP fellows and non-fellows. The results were not statistically significant. Additionally, fellows were compared to a representative sample of PH students from the US, New England, and CT. Discussion: The PHFP has a strong potential to help replenish and diversify the PH workforce and enhance health equity. Future research should examine the long-term impacts of such PH experiential learning initiatives on a large scale.